Published in Vaccine on August 01, 1991
Use of hepadnavirus core proteins as vaccine platforms. Expert Rev Vaccines (2009) 1.01
Localization of an immunodominant domain on baculovirus-produced parvovirus B19 capsids: correlation to a major surface region on the native virus particle. J Virol (1992) 0.92
Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. J Mol Biol (2012) 0.90
Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins. PLoS One (2015) 0.85
Chimeric hepatitis B virus core particles as probes for studying peptide-integrin interactions. J Virol (1996) 0.84
Chimeric hepatitis B virus core particles with parts or copies of the hepatitis C virus core protein. J Virol (1993) 0.80
Expression and immunoreactivity of an epitope of HCV in a foreign epitope presenting system. World J Gastroenterol (2005) 0.76
Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice. Sci Rep (2017) 0.75
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A (1993) 6.14
Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature (1982) 5.50
Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature (1987) 5.26
Unique features of internal initiation of hepatitis C virus RNA translation. EMBO J (1995) 4.44
The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol (1989) 3.53
Propranolol as ocular hypotensive agent. Br J Ophthalmol (1967) 3.42
The complete nucleotide sequence of the RNA coding for the primary translation product of foot and mouth disease virus. Nucleic Acids Res (1984) 3.00
Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol (1976) 2.99
Altered relation of two collagen types in osteogenesis imperfecta. N Engl J Med (1977) 2.93
Chemical basis of antigenic variation in foot-and-mouth disease virus. Nature (1984) 2.52
Internal initiation of translation of hepatitis C virus RNA: the ribosome entry site is at the authentic initiation codon. RNA (1996) 2.45
3'-Terminal nucleotide sequences in the genome RNA of picornaviruses. Nature (1978) 2.40
Self-propelled Leidenfrost droplets. Phys Rev Lett (2006) 2.36
Protein covalently linked to foot-and-mouth disease virus RNA. Nature (1977) 2.35
Location of the initiation site for protein synthesis on foot-and-mouth disease virus RNA by in vitro translation of defined fragments of the RNA. J Virol (1980) 2.34
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother (1997) 2.31
All foot and mouth disease virus serotypes initiate protein synthesis at two separate AUGs. Nucleic Acids Res (1987) 2.22
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother (1995) 2.21
A physico-chemical sub-grouping of the mammalian picornaviruses. J Gen Virol (1973) 2.08
A re-appraisal of the biochemical map of foot-and-mouth disease virus RNA. J Gen Virol (1978) 2.06
Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature (1987) 2.00
Modulation of fibroblast proliferation by oxygen free radicals. Biochem J (1990) 1.97
Sequence and location of the poly C tract in aphtho- and cardiovirus RNA. Nucleic Acids Res (1979) 1.95
The nucleotide sequence of cDNA coding for the structural proteins of foot-and-mouth disease virus. Gene (1982) 1.82
A new and improved method for 3'-end labelling DNA using [alpha-32P]ddATP. Gene (1984) 1.78
Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol (1994) 1.77
Evidence of a generalised connective-tissue defect in Paget's disease of bone. Lancet (1974) 1.76
Molecular cloning of foot and mouth disease virus genome and nucleotide sequences in the structural protein genes. Nature (1981) 1.73
Diazoxide in treatment of primary pulmonary hypertension. Br Heart J (1978) 1.71
A steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain. J Biol Chem (1996) 1.71
More precise location of the polycytidylic acid tract in foot and mouth disease virus RNA. J Virol (1978) 1.69
Comparison of the amino acid sequence of the major immunogen from three serotypes of foot and mouth disease virus. Nucleic Acids Res (1982) 1.66
Potential secondary and tertiary structure in the genomic RNA of foot and mouth disease virus. Nucleic Acids Res (1987) 1.62
Emergency vaccination against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state. Vaccine (1994) 1.61
A new look at osteogenesis imperfecta. A clinical, radiological and biochemical study of forty-two patients. J Bone Joint Surg Br (1975) 1.61
Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature (1987) 1.57
Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia (1989) 1.57
Free radicals and Dupuytren's contracture. Br Med J (Clin Res Ed) (1987) 1.55
Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. Hepatology (1995) 1.50
Beta-sympathetic blockade in hyperthyroidism. Lancet (1966) 1.49
Sequences of vesicular stomatitis virus RNA in the region coding for leader RNA, N protein mRNA, and their junction. Proc Natl Acad Sci U S A (1979) 1.48
Osteogenesis imperfecta. A clinical and biochemical study of a generalized connective tissue disorder. Q J Med (1975) 1.47
The biosynthesis of monoterpenes. Chem Rev (1972) 1.46
Haemodynamic changes during methohexitone anaesthesia in patients with supraventricular arrhythmias. Br J Anaesth (1967) 1.45
Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. Eur Respir J (2007) 1.43
Polymeric collagen of skin in normal sunjects and in patients with inherited connective tissue disorders. Clin Sci (1973) 1.40
Two initiation sites for foot-and-mouth disease virus polyprotein in vivo. J Gen Virol (1985) 1.35
The sequence of foot-and-mouth disease virus RNA to the 5' side of the poly(C) tract. Gene (1985) 1.31
Buoyant density of picornaviruses in caesium salts. J Gen Virol (1971) 1.28
A comparative chemical and serological study of the full and empty particles of foot-and mouth disease virus. J Gen Virol (1975) 1.27
Host cell selection of antigenic variants of foot-and-mouth disease virus. J Gen Virol (1989) 1.26
5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother (1994) 1.25
Na+, K+-ATPase isozyme diversity; comparative biochemistry and physiological implications of novel functional interactions. Biosci Rep (2000) 1.24
Further evidence for multiple proteins in the foot-and-mouth disease virus particle. J Gen Virol (1971) 1.22
Comparison of the antibodies elicited by the individual structural polypeptides of foot-and mouth disease and polio viruses. J Gen Virol (1979) 1.22
Polymeric collagen of skin in osteogenesis imperfecta, homocystinuria and Ehlers-Danlos and Marfan syndromes. Birth Defects Orig Artic Ser (1975) 1.21
Biochemical mapping of the foot-and-mouth disease virus genome. J Gen Virol (1977) 1.21
A pH-sensitive fluor, CypHer 5, used to monitor agonist-induced G protein-coupled receptor internalization in live cells. Biotechniques (2002) 1.20
Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine (1999) 1.20
Release of prostaglandins from bone and muscle after tibial fracture. An experimental study in rabbits. J Bone Joint Surg Br (1981) 1.20
Analysis of ambulatory electrocardiograms in 15 patients during spontaneous ventricular fibrillation with special reference to preceding arrhythmic events. J Am Coll Cardiol (1983) 1.20
Encephalomyocarditis virus antibodies in sera from apparently normal pigs. Vet Rec (1977) 1.19
Orientation of epitopes influences the immunogenicity of synthetic peptide dimers. Eur J Immunol (1988) 1.18
Multiple proteases in foot-and-mouth disease virus replication. J Virol (1984) 1.18
Protection against direct-contact challenge following emergency FMD vaccination of cattle and the effect on virus excretion from the oropharynx. Vaccine (2005) 1.18
Immunological priming with synthetic peptides of foot-and-mouth disease virus. J Gen Virol (1985) 1.18
Immune response to uncoupled peptides of foot-and-mouth disease virus. Immunology (1987) 1.17
Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites. J Gen Virol (1989) 1.17
Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol (1995) 1.14
A high density component in several vertebrate enteroviruses. J Gen Virol (1975) 1.14
Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents. J Gen Virol (1989) 1.13
Localization of the mosaic transmembrane serine protease corin to heart myocytes. Eur J Biochem (2000) 1.13
Neutralizing antibodies to all seven serotypes of foot-and-mouth disease virus elicited by synthetic peptides. Immunology (1990) 1.13
Calcium uptake by sarcoplasmic reticulum of muscle from vitamin D-deficient rabbits. Nature (1974) 1.10
Osteogenesis imperfecta: a new classification. Birth Defects Orig Artic Ser (1975) 1.09
Prenatal prediction of spinal muscular atrophy. J Med Genet (1992) 1.09
Antibody response in pig nasal fluid and serum following foot-and-mouth disease infection or vaccination. J Hyg (Lond) (1983) 1.08
Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob Agents Chemother (1994) 1.07